[Modern treatment of lung cancer with immunotherapy].

Abstract

In the case of non-small cell lung cancer, systemic treatment plays a key role in early, locally advanced as well as metastatic stages. The neoadjuvant approach is represented by the combination of immunotherapy+chemotherapy, while targeted therapy does not yet have an evidence-based place in this indication. Immune checkpoint inhibitor treatment has an important role in clinical practice in adjuvant setting as well. Several trials have also concluded with positive results regarding perioperative immunotherapy. Currently, the role of the multidisciplinary tumor board in the personalized decision-making process is essential. In locally advanced cases, immunotherapy after radiochemotherapy is also evidence-based. In advanced, non oncogene-addicted non-small cell lung cancer, the place of immunotherapy is well defined, both as monotherapy and in combination with chemotherapy. Progress has also been made in small cell lung cancer, both in extensive and limited stages, with immune checkpoint inhibitor treatment.